All Stories

  1. <em>Chlamydia trachomatis</em> ompA Genotype and Clinical Signs of Trachoma in a Longitudinal Tanzanian Cohort
  2. Comparative transcriptomic profiling of human conjunctival epithelial cells and macrophages in response to Chlamydia trachomatis genovars A and B in early- and mid-infection cycles
  3. Evolutionary dynamics in the genome of ocular Chlamydia trachomatis strains from Northern Tanzania following mass drug administration
  4. Multimodal mucosal and systemic immune characterization of a non-human primate trachoma model highlights the critical role of local immunity during acute phase disease
  5. Genomic profiling and characterization of ocular Chlamydia trachomatis reference strain B/HAR36
  6. Evolutionary Dynamics in the Genome of Ocular Chlamydia trachomatis Strains from Northern Tanzania, pre- and post- Mass Drug Administration
  7. Evolutionary Dynamics in the Genome of Ocular Chlamydia trachomatis Strains from Northern Tanzania, pre- and post- Mass Drug Administration
  8. Unravelling Chlamydia trachomatis diversity in Amhara, Ethiopia: MLVA-ompA sequencing as a molecular typing tool for trachoma
  9. Genomic insights into local-scale evolution of ocular Chlamydia trachomatis strains within and between individuals in Gambian trachoma-endemic villages
  10. Genomic insights into local scale evolution of ocularChlamydia trachomatisstrains within and between individuals in Gambian trachoma-endemic villages
  11. Multimodal mucosal and systemic immune characterization of a novel non-human primate trachoma model highlights the critical role of local immunity during acute phase disease
  12. Longitudinal changes in tear cytokines and antimicrobial proteins in trachomatous disease
  13. When Bacteria and Viruses Collide: A Tale of Chlamydia trachomatis and Sexually Transmitted Viruses
  14. Prevalence of five treatable sexually transmitted infections among women in Lower River region of The Gambia
  15. A systems serology approach to the investigation of infection-induced antibody responses and protection in trachoma
  16. A Systems Serology Approach to the Investigation of Infection-Induced Antibody Responses and Protection in Trachoma
  17. Longitudinal Changes in Tear Cytokines and Antimicrobial Proteins in Trachomatous Disease
  18. Sequence based HLA-DRB1, -DQB1 and -DPB1 allele and haplotype frequencies in The Gambia
  19. HLA-A, -B, -C, -DPB1, -DQB1 and -DRB1 allele frequencies of North Tanzanian Maasai
  20. The conjunctival transcriptome in Ethiopians after trichiasis surgery: associations with the development of eyelid contour abnormalities and the effect of oral doxycycline treatment
  21. Editorial: Next-generation sequencing in ophthalmology: The microbiome in ocular health and disease
  22. Prevalence of five curable sexually transmitted infections among women in Lower River Region of The Gambia
  23. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children
  24. Publisher Correction: A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars
  25. Deconvolution of Bulk Transcriptomics Data Suggests Changes in Conjunctival Immune Cell Populations in Trachoma
  26. Association between intestinal bacterial carriage, biomarkers of environmental enteric dysfunction, and stunting in rural Malawian children
  27. Biannual Administrations of Azithromycin and the Gastrointestinal Microbiome of Malawian Children: A Nested Cohort Study Within a Randomized Controlled Trial
  28. Impact of azithromycin mass drug administration on the antibiotic-resistant gut microbiome in children: a randomized, controlled trial
  29. Fecal biomarkers of environmental enteric dysfunction and the gut microbiota of rural Malawian children: An observational study
  30. Mass drug administration with azithromycin for trachoma elimination and the population structure of Streptococcus pneumoniae in the nasopharynx
  31. A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars
  32. Fecal biomarkers of environmental enteric dysfunction and the gut microbiota of rural Malawian children: an observational study
  33. Facial cleanliness indicators by time of day: results of a cross-sectional trachoma prevalence survey in Senegal
  34. DjinniChip: evaluation of a novel molecular rapid diagnostic device for the detection of Chlamydia trachomatis in trachoma-endemic areas
  35. Genomics of Ocular Chlamydia trachomatis After 5 Years of SAFE Interventions for Trachoma in Amhara, Ethiopia
  36. Up to Four Biannual Administrations of Mass Azithromycin Treatment Are Associated with Modest Changes in the Gut Microbiota of Rural Malawian Children
  37. Viability PCR shows that non-ocular surfaces could contribute to transmission of Chlamydia trachomatis infection in trachoma
  38. Mass drug administration with azithromycin for trachoma elimination and the population structure of Streptococcus pneumoniae in the nasopharynx
  39. Immunopathogenesis of Progressive Scarring Trachoma: Results of a 4-Year Longitudinal Study in Tanzanian Children
  40. Whole-genome sequencing of ocular Chlamydia trachomatis isolates from Gadarif State, Sudan
  41. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal
  42. The conjunctival transcriptome in Ethiopians after trichiasis surgery: associations with the development of eyelid contour abnormalities and the effect of oral doxycycline treatment
  43. Conjunctival Microbiome-Host Responses Are Associated With Impaired Epithelial Cell Health in Both Early and Late Stages of Trachoma
  44. Influenza Vaccination Primes Human Myeloid Cell Cytokine Secretion and NK Cell Function
  45. Progression of scarring trachoma in Tanzanian children: A four-year cohort study
  46. Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community
  47. Pathway-Wide Genetic Risks in Chlamydial Infections Overlap between Tissue Tropisms: A Genome-Wide Association Scan
  48. Is Trachoma disease severity linked to ocular Chlamydia trachomatis pathogen strain variation
  49. Conjunctival transcriptome profiling of Solomon Islanders with active trachoma in the absence of Chlamydia trachomatis infection
  50. Evaluation of a Chlamydia trachomatis-specific, commercial, real-time PCR for use with ocular swabs
  51. Active Trachoma Cases in the Solomon Islands Have Varied Polymicrobial Community Structures but Do Not Associate with Individual Non-Chlamydial Pathogens of the Eye
  52. An outbreak of acute haemorrhagic conjunctivitis associated with coxsackievirus A24 variant in The Gambia, West Africa
  53. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa
  54. Pathways-wide genetic risks in Chlamydial infections overlap between tissue tropisms: A genome-wide association scan
  55. Population-based analysis of ocularChlamydia trachomatisin trachoma-endemic West African communities identifies genomic markers of disease severity
  56. Immunofibrogenic Gene Expression Patterns in Tanzanian Children with Ocular Chlamydia trachomatis Infection, Active Trachoma and Scarring: Baseline Results of a 4-Year Longitudinal Study
  57. Genome-wide profiling of humoral immunity and pathogen genes under selection identifies immune evasion tactics of Chlamydia trachomatis during ocular infection
  58. Reduced-cost Chlamydia trachomatis -specific multiplex real-time PCR diagnostic assay evaluated for ocular swabs and use by trachoma research programmes
  59. Population-based prevalence survey of follicular trachoma and trachomatous trichiasis in the Casamance region of Senegal
  60. Persistence of Innate Immune Pathways in Late Stage Human Bacterial and Fungal Keratitis: Results from a Comparative Transcriptome Analysis
  61. Spatial clustering of high load ocular Chlamydia trachomatis infection in trachoma: a cross-sectional population-based study
  62. Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control
  63. Profiling and validation of individual and patterns of Chlamydia trachomatis-specific antibody responses in trachomatous trichiasis
  64. miRNAs that associate with conjunctival inflammation and ocular Chlamydia trachomatis infection do not predict progressive disease
  65. Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies
  66. The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment
  67. Blinding Trachoma: Systematic Review of Rates and Risk Factors for Progressive Disease
  68. Mycobacterium leprae Activates Toll-Like Receptor-4 Signaling and Expression on Macrophages Depending on Previous Bacillus Calmette-Guerin Vaccination
  69. Differential frequency of NKG2C/KLRC2 deletion in distinct African populations and susceptibility to Trachoma: a new method for imputation of KLRC2 genotypes from SNP genotyping data
  70. Increased Epithelial Expression of CTGF and S100A7 with Elevated Subepithelial Expression of IL-1β in Trachomatous Trichiasis
  71. Immunohistochemical Analysis of Scarring Trachoma Indicates Infiltration by Natural Killer and Undefined CD45 Negative Cells
  72. Ocular chlamydial genomic variants and disease severity in trachoma: a cross-sectional population-based genome-wide association study
  73. Can corneal pannus with trachomatous inflammation – follicular be used in combination as an improved specific clinical sign for current ocular Chlamydia trachomatis infection?
  74. Inverse relationship between microRNA-155 and -184 expression with increasing conjunctival inflammation during ocular Chlamydia trachomatis infection
  75. Conjunctival fibrosis and the innate barriers to Chlamydia trachomatis intracellular infection: a genome wide association study
  76. Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies
  77. Pathogenesis of Progressive Scarring Trachoma in Ethiopia and Tanzania and Its Implications for Disease Control: Two Cohort Studies
  78. Costs of Testing for Ocular Chlamydia trachomatis Infection Compared to Mass Drug Administration for Trachoma in The Gambia: Application of Results from the PRET Study
  79. Serology for Trachoma Surveillance after Cessation of Mass Drug Administration
  80. Trachoma and Ocular Chlamydial Infection in the Era of Genomics
  81. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control
  82. Whole-genome enrichment and sequencing of Chlamydia trachomatisdirectly from clinical samples
  83. The conjunctival microbiome in health and trachomatous disease: a case control study
  84. Non-Participation during Azithromycin Mass Treatment for Trachoma in The Gambia: Heterogeneity and Risk Factors
  85. Risk Factors for Active Trachoma and Ocular Chlamydia trachomatis Infection in Treatment-Naïve Trachoma-Hyperendemic Communities of the Bijagós Archipelago, Guinea Bissau
  86. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross-sectional surveys in the Gambia
  87. Will droplet digital PCR become the test of choice for detecting and quantifying ocularChlamydia trachomatisinfection? Maybe
  88. Conjunctival Scarring in Trachoma Is Associated with the HLA-C Ligand of KIR and Is Exacerbated by Heterozygosity at KIR2DL2/KIR2DL3
  89. Towards a safe and effective chlamydial vaccine: Lessons from the eye
  90. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children
  91. Killer-cell Immunoglobulin-like Receptor gene linkage and copy number variation analysis by droplet digital PCR
  92. Plasmid Copy Number and Disease Severity in Naturally Occurring Ocular Chlamydia trachomatis Infection
  93. In vivo confocal microscopy and histopathology of the conjunctiva in trachomatous scarring and normal tissue: a systematic comparison
  94. Association between Ocular Bacterial Carriage and Follicular Trachoma Following Mass Azithromycin Distribution in The Gambia
  95. Correction: Mass Treatment with Azithromycin for Trachoma: When Is One Round Enough? Results from the PRET Trial in The Gambia
  96. Mass Treatment with Azithromycin for Trachoma: When Is One Round Enough? Results from the PRET Trial in The Gambia
  97. Development and Evaluation of a Next-Generation Digital PCR Diagnostic Assay for Ocular Chlamydia trachomatis Infections
  98. Conjunctival MicroRNA Expression in Inflammatory Trachomatous Scarring
  99. Trachoma: Protective and Pathogenic Ocular Immune Responses to Chlamydia trachomatis
  100. Biogeography of the ecosystems of the healthy human body
  101. Eyescores: an open platform for secure electronic data and photographic evidence collection in ophthalmological field studies
  102. Post-Operative Recurrent Trachomatous Trichiasis Is Associated with Increased Conjunctival Expression of S100A7 (Psoriasin)
  103. A Diagnostics Platform for the Integrated Mapping, Monitoring, and Surveillance of Neglected Tropical Diseases: Rationale and Target Product Profiles
  104. Genome-Wide Identification ofChlamydia trachomatisAntigens Associated with Trachomatous Trichiasis
  105. Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing
  106. Innate Immune Responses and Modified Extracellular Matrix Regulation Characterize Bacterial Infection and Cellular/Connective Tissue Changes in Scarring Trachoma
  107. Active Trachoma Is Associated with Increased Conjunctival Expression ofIL17Aand Profibrotic Cytokines
  108. Diagnostic Accuracy of a Prototype Point-of-Care Test for Ocular Chlamydia trachomatis under Field Conditions in The Gambia and Senegal
  109. Design and Baseline Data of a Randomized Trial to Evaluate Coverage and Frequency of Mass Treatment with Azithromycin: The Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia
  110. Systemic effector and regulatory immune responses to chlamydial antigens in trachomatous trichiasis
  111. Trachoma Prevalence and Associated Risk Factors in The Gambia and Tanzania: Baseline Results of a Cluster Randomised Controlled Trial
  112. Conjunctival Transcriptome in Scarring Trachoma
  113. Profound and Sustained Reduction in Chlamydia trachomatis in The Gambia: A Five-Year Longitudinal Study of Trachoma Endemic Communities
  114. Trichiasis Surgery in The Gambia: A 4-Year Prospective Study
  115. Human Conjunctival Transcriptome Analysis Reveals the Prominence of Innate Defense in Chlamydia trachomatis Infection
  116. Pathway-Focused Arrays Reveal Increased Matrix Metalloproteinase-7 (Matrilysin) Transcription in Trachomatous Trichiasis
  117. Phylogenetic Analysis of Chlamydia trachomatis Tarp and Correlation with Clinical Phenotype
  118. Conjunctival Expression of Matrix Metalloproteinase and Proinflammatory Cytokine Genes after Trichiasis Surgery
  119. Haptoglobin and Sickle Cell Polymorphisms and Risk of Active Trachoma in Gambian Children
  120. Active Trachoma and Ocular Chlamydia trachomatis Infection in Two Gambian Regions: On Course for Elimination by 2020?
  121. Innate immunity in ocular Chlamydia trachomatis infection: contribution of IL8 and CSF2 gene variants to risk of trachomatous scarring in Gambians
  122. Dirty hands: bacteria of faecal origin on commuters' hands
  123. When Can Antibiotic Treatments for Trachoma Be Discontinued? Graduating Communities in Three African Countries
  124. The Development of an Age-Structured Model for Trachoma Transmission Dynamics, Pathogenesis and Control
  125. A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice
  126. Revealing the History of Sheep Domestication Using Retrovirus Integrations
  127. Estimating Household and Community Transmission of Ocular Chlamydia trachomatis
  128. Co-evolution of genomes and plasmids within Chlamydia trachomatis and the emergence in Sweden of a new variant strain
  129. Risk factors for active trachoma in The Gambia
  130. Chlamydia trachomatis ompA Variants in Trachoma: What Do They Tell Us?
  131. Analysis of flow cytometry data using an automatic processing tool
  132. Two Doses of Azithromycin to Eliminate Trachoma in a Tanzanian Community
  133. Pathogenic Diversity amongChlamydia trachomatisOcular Strains in Nonhuman Primates Is Affected by Subtle Genomic Variations
  134. Susceptibility to sequelae of human ocular chlamydial infection associated with allelic variation in IL10 cis-regulation
  135. FOXP3 gene expression in a tuberculosis case contact study
  136. Genetic variation at the TNF locus and the risk of severe sequelae of ocular Chlamydia trachomatis infection in Gambians
  137. Chlamydial Positivity of Nasal Discharge at Baseline Is Associated with Ocular Chlamydial Positivity 2 Months following Azithromycin Treatment
  138. Conjunctival FOXP3 Expression in Trachoma: Do Regulatory T Cells Have a Role in Human Ocular Chlamydia trachomatis Infection?
  139. A coding polymorphism in matrix metalloproteinase 9 reduces risk of scarring sequelae of ocular Chlamydia trachomatisinfection
  140. The Frequency of Chlamydia trachomatis Major Outer Membrane Protein-Specific CD8+ T Lymphocytes in Active Trachoma Is Associated with Current Ocular Infection
  141. Conjunctival Chlamydial 16S Ribosomal RNA Expression in Trachoma: Is Chlamydial Metabolic Activity Required for Disease to Develop?
  142. Temporal cytokine gene expression patterns in subjects with trachoma identify distinct conjunctival responses associated with infection
  143. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study
  144. Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey
  145. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study
  146. Risk of trachomatous scarring and trichiasis in Gambians varies with SNP haplotypes at the interferon-gamma and interleukin-10 loci
  147. An index of community ocular Chlamydia trachomatis load for control of trachoma
  148. Mass Treatment and the Effect on the Load ofChlamydia trachomatisInfection in a Trachoma-Hyperendemic Community
  149. Th2 induction by Nippostrongylus secreted antigens in mice deficient in B cells, eosinophils or MHC Class I-related receptors
  150. Cytokine and Fibrogenic Gene Expression in the Conjunctivas of Subjects from a Gambian Community Where Trachoma Is Endemic
  151. Mass Treatment with Single-Dose Azithromycin for Trachoma
  152. Selective maturation of dendritic cells byNippostrongylus brasiliensis-secreted proteins drives Th2 immune responses
  153. Cytokine expression and regulation in skin lesions of leprosy patients in type 1 reactions
  154. Strategies for control of trachoma: observational study with quantitative PCR
  155. Which Members of a Community Need Antibiotics to Control Trachoma? ConjunctivalChlamydia trachomatisInfection Load in Gambian Villages
  156. Plasmodium falciparum infection of the placenta affects newborn immune responses
  157. Strategies for control of trachoma: observational study with quantitative PCR
  158. Proteins secreted by the parasitic nematodeNippostrongylus brasiliensis act as adjuvants for Th2 responses
  159. Vaccination against helminth parasites - the ultimate challenge for vaccinologists?
  160. Jaagsiekte Retrovirus Is Widely Distributed both in T and B Lymphocytes and in Mononuclear Phagocytes of Sheep with Naturally and Experimentally Acquired Pulmonary Adenomatosis
  161. Early Interleukin–4: Its Role in the Switch towards a Th2 Response and IgE–Mediated Allergy
  162. Parasite immunity: Pathways for expelling intestinal helminths
  163. Antibody Response to the 60‐kDa Chlamydial Heat‐Shock Protein Is Associated with Scarring Trachoma
  164. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid
  165. Synthetic peptides based on Chlamydia trachomatis antigens identify cytotoxic T lymphocyte responses in subjects from a trachoma‐endemic population
  166. Jaagsiekte retrovirus establishes a disseminated infection of the lymphoid tissues of sheep affected by pulmonary adenomatosis
  167. T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring
  168. HLA Class I and II Polymorphisms and Trachomatous Scarring in a Chlamydia trachomatis-Endemic Population
  169. Subjects recovering from human ocular chlamydial infection have enhanced lymphoproliferative responses to chlamydial antigens compared with those of persistently diseased controls
  170. Conjunctival Scarring in Trachoma Is Associated with Depressed Cell-Mediated Immune Responses to Chlamydial Antigens
  171. Chlamydia pneumoniae and atherosclerosis
  172. Lymphocyte proliferative responses to chlamydial antigens in human chlamydial eye infections
  173. Experimental Autoimmune Glomerulonephritis Induced by Homologous and Isologous Glomerular Basement Membrane in Brown-Norway Rats